Page Image

2025 ASCO Annual Meeting Coverage

Focus on HER2+ mBC
Neoadjuvant Immunity: Oncolytic Virus + Chemo Shows Promise in Early TNBC
TVEC plus chemo shows promise in early TNBC, boosting immune response and survival with favorable safety profile.
Advertisement
Advertisement
Advertisement